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Abstract 
Aims: Several models for predicting the prognosis of heart failure (HF) patients have been 
developed, but all of them focus on a single outcome variable, such as all-cause mortality. 
The purpose of this study was to develop a multi-state model for simultaneously predicting 
survival and HF-related hospitalization in patients discharged alive from hospital after 
recovery from acute HF. 
Methods and results: The model was derived in the COACH cohort, a multi-center, 
randomized controlled trial in which 1023 patients were enrolled after hospitalization because 
of HF. External validation was attained with the FINN-AKVA cohort, a prospective, multi-
center study with 620 patients hospitalized due to acute HF. The observed versus predicted 
18-month survival was 72.1% versus 72.3% in the derivation cohort and 71.4% versus 71.2% 
in the validation cohort. The corresponding values of the c statistic were 0.733 (95% CI: 
0.705-0.761) and 0.702 (95% CI: 0.663-0.744), respectively. The model’s accuracy in 
predicting HF hospitalization was excellent, with predicted values that closely resembled the 
values as observed in the derivation cohort.  
Conclusion: The COACH risk engine accurately predicted survival and various measures of 
recurrent hospitalization in (acute) HF patients. It may therefore become a valuable tool in 
improving and personalizing patient care and optimizing the use of scarce health-care 
resources. 
 
Keywords: epidemiology; heart failure; prediction; prognosis; multi-state modeling 
 
 2 
Introduction 
Heart failure (HF), one of the major causes of death in Western nations, is characterized by a 
poor prognosis: up to 70% of all HF patients die within 5 years after their first hospital 
admission (1). Furthermore, HF is associated with high direct costs, accounting for 1 to 2% of 
total health-care expenditures (2). Classification of HF patients into different risk groups 
based on their expected prognosis is therefore of utmost importance to improve and 
personalize patient care and to optimize the use of scarce health-care resources. 
To assist health-care providers in identifying those patients who are at risk for a poor 
prognosis, various clinical prediction models have been developed (3-11). Although these 
models generally differ on the selected endpoints and/or the included risk factors, they have 
much in common when looking at them from a more methodological perspective. First, as far 
as the clinical context is concerned, the existing models focus either on predicting medium- to 
long-term prognosis (≥ 1 year) in chronic HF patients or on predicting in-hospital or short-
term, post-discharge prognosis in acute HF patients. Models for predicting longer-term, post-
discharge prognosis in acute HF patients, in contrast, have so far not been developed. Second, 
as far as the selection of endpoints is concerned, existing models focus on a single outcome 
variable, such as all-cause mortality or HF hospitalization. Although the outcome variable is 
frequently defined as a combined endpoint, the predictions remain aggregated at the level of a 
single composite measure, i.e., predictions at the level of the composite measure are not 
broken down into marginal predictions at the level of the measure’s individual components.  
In response to the methodological considerations given above, the purpose of this 
paper was to develop a multi-state model for predicting 18-month survival and three different 
measures of recurrent HF hospitalization (i.e., cumulative incidence function of HF 
hospitalization, number of recurrent HF hospitalizations, and days lost due to HF 
hospitalization) in patients discharged alive from the hospital after recovery from acute HF. 
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Methods 
Study cohorts 
We used data previously collected in two cohorts of HF patients. One of these cohorts, the 
Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure 
(COACH), was used to develop the model, whereas the other cohort, the Finish Acute Heart 
Failure Study (FINN-AKVA), was used to externally validate the model.  
COACH was a multi-center, randomized controlled trial in which patients hospitalized 
with HF as the primary diagnosis were randomly assigned to either the control group (follow-
up by a cardiologist) or to one of the two intervention groups with basic or intensive 
additional support by a nurse specialized in the management of HF patients (12,13). All 
patients where 18 years or older and had evidence of structural cardiac dysfunction as shown 
at cardiovascular imaging. The major reasons for exclusion were concomitant enrollment in 
another trial, ongoing assessment for heart transplantation, recent history of an invasive 
procedure or cardiac surgery within the last 6 months, or plan of undergoing such a procedure 
within the next 3 months. Out of the 1049 patients that were randomized, 1023 were 
discharged alive and were followed up for a maximum of 18 months after hospital discharge. 
This latter group forms the COACH study population.  
FINN-AKVA was a multi-center, prospective study in which 620 hospitalized HF 
patients participated (14). Both patients with new-onset acute HF and patients with 
exacerbation of chronic HF were included. Patients with high-output HF were not included. 
For the purpose of the present study, we used the data collected on all 576 patients who were 
discharged alive from the hospital.  
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Covariate measurement 
In both cohorts, NT-proBNP measurements were performed at a core laboratory using a 
commercially available electrochemiluminescent sandwich immunoassay (Elecsys proBNP, 
Roche Diagnostics, Mannheim, Germany), with an analytical range of 5.0-35,000 pg/ml. 
Estimated glomerular filtration rate (eGFR) values were calculated using the Modification of 
Diet in Renal Disease formula based on the creatinine measurements taken at hospital 
discharge. Left ventricular ejection fraction (LVEF) was determined based on 
echocardiography data collected during the index admission. 
Model structure 
COACH risk engine is a multi-state model for predicting survival and various measures of 
recurrent HF hospitalization in patients discharged alive from the hospital after recovery from 
acute HF. The model consists of three discrete health states, discharged alive from hospital, 
hospitalization because of HF (defined as an unplanned overnight stay in a hospital because 
of progression of HF or as a direct result of HF), and dead, and a transition probability matrix 
P, whose elements pij represent the probability that when leaving health state i, the next health 
state will be j (see Figure 1 for a schematic representation). The distribution of the amount of 
time that a patient spends in the discharged alive from hospital state before making a 
transition into a different health state (i.e., hospitalization because of HF or dead) was 
estimated by fitting a Weibull model to the composite endpoint of HF hospitalization or death 
(the primary endpoint of the COACH study). Similarly, to estimate the distribution of the 
amount of time that a patient spends in the hospitalization because of HF state, a log-logistic 
model was fitted to the observed length of stay in patients that were hospitalized because of 
HF. The specific likelihoods of transiting from one health state to the next, i.e. the elements of 
the transition matrix P, were determined using logistic regression. For a more detailed 
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description of the model’s regression equations, the reader is referred to online data 
supplement I. 
Parameter estimation 
The procedures used to fit the four regression equations to the observed outcomes in the 
COACH study population were as follows. First, a set of candidate predictor variables (online 
data supplement II) to consider during model building was obtained by selecting from the 
COACH study those variables that according to previous studies could be potential predictors 
for survival and hospital readmission. As missing values were present in several of the 
selected candidate predictors, multiple imputation was used to obtain ten imputed data sets. 
Model building was subsequently performed by applying the backward stepwise selection 
procedure recommended by Wood et al (15). The nominal significance levels for variable 
exclusion in the backward steps and variable inclusion in the forward steps were set equal to 
10% and 9.9%, respectively. Once a final model had been selected, Rubin’s rules were used to 
obtain pooled estimates of the regression coefficients and their standard errors (16).  
Simulation algorithm 
For a description of the applied simulation algorithm, the reader is referred to online data 
supplement III. 
Model validation 
Survival 
Model performance on survival was internally and externally validated by considering 
calibration and discrimination after 18 months of follow-up in the COACH study and 18 
months of follow-up in the FINN-AKVA study, respectively. Calibration was determined by 
comparing the mean predicted survival to the mean observed survival (Kaplan-Meier 
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estimate) by deciles of predicted survival (mean across all simulation runs). Discrimination 
was determined by calculating the value of the c statistic (17), using non-parametric 
bootstrapping to obtain a corresponding 95% confidence interval.  
HF hospitalization 
Model performance on hospitalization could not be assessed externally as data on this 
endpoint was not collected during the FINN-AKVA study. Internal validation was established 
by considering three different measures of HF hospitalization: the cumulative incidence 
function of HF hospitalization, the number of HF hospitalizations, and the number of days 
lost due to HF hospitalization. The model’s accuracy in predicting the cumulative incidence 
function of HF hospitalization was assessed by considering calibration and discrimination. 
Calibration was determined by comparing the mean predicted 18-month risk of HF 
hospitalization to the mean observed 18-month risk of HF hospitalization (non-parametric 
cause-specific hazards estimate (18)) by deciles of predicted 18-month risk of HF 
hospitalization. Discrimination was determined by using a time-dependent variant of the c 
statistic (19), applying Wolbers et al.’s (20) adapted definition of the risk set to account for 
the occurrence of death as a competing risk for the event of interest. Model performance on 
the other two measures of HF hospitalization was assessed by comparing the observed 
frequencies of HF hospitalization (days lost due to HF hospitalization) to the predicted 
frequencies of HF hospitalization (days lost due to HF hospitalization) after 18 months of 
follow-up. To account for lost-to-follow-up censoring, the observed frequencies (days lost due 
to HF hospitalization) were estimated by using the partitioned estimator proposed by Bang 
and Tsiatis (21). The predicted values for each of the three measures of HF hospitalization 
were obtained by taking the mean across all simulation runs. 
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Handling of missing values 
Similar as during model derivation, missing values on the predictor variables during model 
validation were dealt with by using multiple imputation. In FINN-AKVA, systolic  blood 
pressure (SBP), diastolic blood pressure (DBP), and serum sodium were only available at 
hospital admission. For serum sodium, the admission values were carried forward to hospital 
discharge. For SBP and DBP, the missing discharge values were imputed from the other 
predictor variables based on two linear regression equations derived from the COACH study. 
Results 
Patient characteristics 
An overview of the patient characteristics in COACH (derivation cohort) and FINN-AKVA 
(validation cohort) is provided in Table 1. Compared to the COACH study, the FINN-AKVA 
study had a larger fraction of patients with preserved LVEF as is evident by a larger fraction 
of female patients, higher age, and higher LVEF. However, the ranges of the variables under 
consideration were still comparable. 
Model derivation 
During the 18 months of follow-up in the COACH study, 411 patients (40%) reached the 
combined endpoint of HF hospitalization or death. Out of these patients, 38% had died and 
62% had been hospitalized for HF. In total, 356 HF hospitalizations were recorded. The 
median duration of these hospital admissions was 9 days (interquartile range: 5-17 days), and 
the incidence of in-hospital mortality was 16%. 
 The beta coefficients and corresponding hazard and odds ratios for the final models of 
the time-to-event distributions and transition probabilities underlying the COACH risk engine 
are listed in Table 2 and Table 3, respectively. All variables entered the models as linear 
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terms, except for NT-proBNP for which a log transformation was applied to increase the 
predictability of this covariate. 
Model validation 
The observed versus predicted 18-month survival was 72.1% versus 72.3% in the derivation 
cohort and 71.4% versus 71.2% in the validation cohort; the observed versus predicted 18-
month risk of HF hospitalization was 26.0% versus 26.7% (derivation cohort only). The 
calibration plots (Figure 2 and Figure 3) indicate a good calibration, with most of the 
predicted survival and HF hospitalization estimates well within the 95% confidence intervals 
of the corresponding observed survival and HF hospitalization estimates. For the survival 
outcome, the discriminative ability of the model was moderate with values of the c statistic of 
0.733 (95% CI: 0.705-0.761) and 0.702 (95% CI: 0.663-0.744) for the derivation and 
validation cohort, respectively. The model’s discriminative ability for the HF hospitalization 
outcome was slightly poorer with a value of the c statistic of 0.664 (95% CI: 0.631-0.695). 
The model’s accuracy in predicting the other two measures of HF hospitalization was 
excellent (Figure 4), with predicted values that closely resembled the values as observed in 
the COACH study cohort. 
Discussion 
This paper presented a multi-state model for predicting 18-month survival and three different 
measures of HF hospitalization in a broad spectrum of patients discharged alive from the 
hospital after recovery from acute HF. Underlying the COACH risk engine are four 
parametric equations, for which a total of 14 demographical, clinical, and biological risk 
factors were identified. Given a patient’s values for these risk factors, Monte Carlo simulation 
could successfully be applied to predict the occurrence of the selected outcome variables. 
 Although we identified several variables that were independently associated with a 
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patient’s length of stay (LOS) in the hospital, none of these associations were highly 
significant. Out of all considered variables, eGFR and LVEF had the lowest and second 
lowest p-values, respectively. That eGFR was found to be an independent predictor of LOS is 
not surprising as previous studies already showed that HF patients with impaired renal 
function had a significantly increased LOS (22,23). The negative association between LVEF 
and LOS seems more controversial, however. Although this finding is consistent with Harjaj 
et al (24), there are also studies in which LVEF was not independently associated with LOS 
(25,26). Data from two large American registries do suggest that there are statistically 
significant differences in LOS between patients with preserved and reduced LVEF, but that 
the magnitude of these differences are so small that they may not be clinically relevant 
(27,28). This also seems to hold for the results presented in this paper: although the 
association between LVEF and the time to hospital discharge was statistically significant, a 
relative odds of 1.15 for every 10% increase in LVEF does not directly indicate a clinically 
relevant effect size. Renal function was also highly predictive of the combined endpoint of HF 
hospitalization or death. Other strong predictors for this endpoint were sex, myocardial 
infarction, serum sodium, and previous HF hospitalization. LVEF was not found to be 
independently associated with the occurrence of these two adverse events in the COACH 
study population. Similar as for the prediction of LOS, this finding is concordant with some 
of the previously published risk models (8,9) but discordant with others (7,10). The added 
value of including LVEF as one of the predictors in a prognostic model therefore remains 
uncertain. 
 As female sex was found to be protective for both the combined endpoint of HF 
hospitalization or death (Equation 1) and the conditional probability of death given HF 
hospitalization or death (Equation 3), the average predicted survival in female patients will be 
longer than the average predicted survival in male patients. Likewise, it follows that our 
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multi-state model will show a negative association between NT-proBNP and survival and a 
positive association between pulse pressure and survival. This latter finding may be somewhat 
surprising as the association between pulse pressure and survival was previously found to be 
negative in patients with chronic HF (29). It is however consistent with Aronson and Burger 
(30), who showed that in the presence of decompensated HF, reduced pulse pressure is an 
independent predictor of poor outcome. 
Existing risk functions for predicting survival or recurrent hospitalization in HF 
patients have been derived by fitting a single regression equation to the data at hand. From a 
multi-state modeling perspective, such risk functions can be seen as two-state models with 
one starting state (i.e., being alive at time 0) and one absorbing state reflecting the occurrence 
of the event of interest (e.g., death or recurrent hospitalization) (31). The multi-state model 
presented in this paper takes the modeling of a patient’s disease progression one step further 
by introducing HF hospitalization as an intermediate state through which a patient’s 
progression towards death can occur. Compared to the two-state models underlying most of 
the existing risk functions, our multi-state model has two major advantages. First, previous 
research has shown that a patient’s risk of death is greatest in the early post-discharge period 
and then declines progressively over time until the next HF hospitalization occurs (32). In our 
multi-state model, this dependency between the probability of dying in a certain time period 
and the time since the last HF hospitalization is explicitly accounted for when estimating a 
patient’s survival function. This is achieved by considering all possible pathways through 
which a transition towards the dead state can occur (i.e., directly moving from discharged 
alive from the hospital to dead or moving to dead through one or more visits of the 
hospitalization because of HF state). The second advantage of our multi-state modeling 
approach over the traditional approach of fitting a single regression equation to the data at 
hand concerns the prediction of the intermediate event (i.e., HF hospitalization). It is well 
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known from the competing-risks literature that standard survival analysis leads to biased 
results when competing events may preclude the occurrence of the event of interest (18). 
These so-called competing risks are clearly present in our situation where the event HF 
hospitalization will never be observed in patients that die beforehand. In contrast to some of 
the previously published risk functions for predicting recurrent hospitalization in HF patients 
(33), the presence of death as a competing risk is adequately accounted for when using our 
multi-state model to predict the cumulative incidence function of HF hospitalization.  
A limitation of this study is that apart from age and previous HF hospitalization, all 
risk factors were treated as fixed-time covariates, meaning that their values were assumed to 
remain constant across the 18-month prediction period. To explore whether this assumption 
could still be considered reasonable for the laboratory measurements, we performed a 
sensitivity analysis by refitting a simplified variant of the model consisting of demographical 
and clinical variables only. Compared to the more elaborate variant presented in this paper, 
the simplified model performed considerably worse in predicting the survival outcome and 
similar in predicting the HF hospitalization outcomes. Including the laboratory measurements 
as fixed-time covariates therefore seems reasonable when using our model to make short- to 
medium-term predictions (i.e., up to 18 months). Care should however be taken when using 
the model to make long-term predictions of a patient’s disease progression as this would 
ideally require joint modeling of the course of time of the continuous risk factors and the 
time-to-event distributions of the considered outcome measures (34). Another limitation of 
this study is that the model’s performance on HF hospitalization could only be assessed 
internally as data on this endpoint was not collected in the FINN-AKVA study. 
Although the validation cohort was quite different from the derivation cohort, i.e., 
patients with preserved LVEF were much more heavily populated in the FINN-AKVA study 
compared to the COACH study, these differences in case mix did not have a profound impact 
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on model calibration: the 18-month survival as predicted by our multi-state model was still 
very close to the 18-month survival as observed in the FINN-AKVA study (71.2% versus 
71.4%, respectively). Hence, the two study cohorts can still be regarded as plausibly related as 
there were no systematic differences in mortality incidence between COACH and FINN-
AKVA that could not be explained by different distributions of the predictor variables 
(35,36). Care should however be taken when applying our risk engine in settings that include 
patients who where not represented in the COACH study. For example, if we compare the 
baseline characteristics of the COACH study population to the baseline characteristics of the 
patients in two large American registries (27,28), we see that about 20% of the patients in the 
registries were African American, whereas the vast majority of the patients in the COACH 
study were Caucasian. Also, less than 80% of the patients in the two American registries had 
Medicare/Medicaid insurance, whereas health care insurance is obligatory in the Netherlands. 
Such demographical and cultural differences between North-West Europe and other regions 
of the world may imply that the predictive ability of our model is substantially reduced when 
it is applied in these latter settings. 
To conclude, the COACH risk engine successfully predicted survival and HF 
hospitalization in a broad spectrum of acute HF patients. To allow for convenient application 
of the model in practice, a user-friendly software implementation has been developed in Java. 
This implementation is freely available at: https://github.com/Postmus/coach/wiki/COACH-
Risk-Engine. 
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Table 1. Patient characteristics at hospital discharge∗ 
 COACH† FINN-AKVA‡  
Number of patients 1023 576 
Age, years (mean ± SD) 71 ± 11 74 ± 10 
Female sex 38% 49% 
Diabetes 28% 32% 
COPD 26% 12% 
Hypertension 43% 54% 
Stroke 10% 13% 
Myocardial infarction 43% 27% 
Peripheral arterial disease 16% 10% 
Atrial fibrillation 44% 30% 
LVEF (mean ± SD) 34 ± 14 45 ± 16 
Previous HF hospitalization 33% 52% 
BMI, kg/m2, (mean ± SD) 27 ± 5 29 ± 7 
SBP, mm Hg (mean ± SD) 118 ± 21 149 ± 33 
                                                 
∗
 Abbreviations: CODP, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; BMI, 
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; NT-proBNP, N-terminal 
prohormone B-type natriuretic peptipe; eGFR, estimated glomerular filtration rate. 
 
†
 SBP, DBP, LVEF, and laboratory values were assessed just before hospital discharge. If a discharge value on 
LVEF was missing, it was replaced by the closest available measurement after hospital discharge. 
 
‡
 The risk factors SBP, DBP, serum sodium, hemoglobin, and NT-proBNP were not available at hospital 
discharge. For these variables, we used the measurements as taken closest to discharge (admission values for 
SBP, DBP, and serum sodium, and 48-hours values for hemoglobin and NT-proBNP). 
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DBP, mm Hg (mean ± SD) 68 ± 12 83 ± 20 
log(NT-proBNP), pg/mL (mean ± SD) 7.85 ± 1.19 8.24 ± 1.23 
eGFR, mL/min/1.73 m2 (mean ± SD) 55 ± 21 57 ± 22 
Serum sodium, mmol/L (mean ± SD) 139 ± 4 138 ± 5 
Hemoglobin, g/L (mean ± SD) 132 ± 20 127 ± 18 
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Table 2. Results from the parametric survival analysis (Equations 1 and 2) 
 Equation 1 Equation 2 
State: Discharged alive from hospital Hospitalization because of HF 
Functional form: Weibull Log logistic 
Parameters Coefficient (s.e.) HR Coefficient (s.e.) OR 
ρ 0.719  (0.051)  1.931 (0.023)  
α 0.816 (1.567)  -6.298 (0.780)  
Age   0.014 (0.008) 1.014 
Female sex -0.287 (0.096) 0.750   
DBP -0.015 (0.004) 0.985   
Pulse pressure (SBP-DBP) -0.005 (0.003) 0.995   
Stroke 0.275 (0.123) 1.317 0.483 (0.269) 1.621 
Myocardial infarction 0.296 (0.090) 1.344   
Atrial fibrillation 0.172 (0.088) 1.188   
Peripheral arterial disease 0.177 (0.103) 1.194 -0.374 (0.213) 0.688 
Diabetes 0.222 (0.093) 1.249   
LVEF   0.014  (0.007) 1.014 
Previous HF hospitalization 0.648 (0.098) 1.912   
Serum sodium -0.036 (0.011) 0.965   
eGFR  -0.013 (0.003) 0.987 0.012 (0.005) 1.012 
log(NT-proBNP) 0.073 (0.041) 1.076   
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Table 3. Results from the logistic regression (Equations 3 and 4) 
 Equation 3 Equation 4 
Probability: )1( 131213 ppp −=  )1( 232123 ppp −=  
Functional form: Logistic Logistic 
Parameters Coefficient (s.e.) OR Coefficient (s.e.)  OR 
α -4.206 (0.868)   -3.092 (1.304)  
Age 0.047 (0.010) 1.048   
Female sex -0.534 (0.204) 0.586   
DBP   -0.025 (0.014) 0.975 
Pulse pressure -0.018 (0.006) 0.982   
Diabetes   0.649 (0.302) 1.914 
Previous HF hospitalization -0.362 (0.185) 0.696   
log(NT-proBNP) 0.186 (0.069) 1.204 0.348 (0.131) 1.416 
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Figure legends 
Figure 1. A schematic representation of the multi-state model 
Figure 2. Calibration plots of mean predicted survival versus mean observed survival 
(Kaplan-Meier estimate + corresponding 95% confidence interval) by deciles of predicted 
survival for the derivation cohort (left) and the validation cohort (right) 
Figure 3. Calibration plot of mean predicted HF hospitalization versus mean observed HF 
hospitalization (cause-specific hazards estimate + corresponding 95% confidence interval) by 
deciles of predicted HF hospitalization 
Figure 4. Observed versus predicted number of HF hospitalizations (left) and observed versus 
predicted number of days lost due to HF hospitalization (right) after 18 months of follow-up 
